Maynard Um
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data
-
-
-
-
-
-
-
After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more
-
-
-
-
-
-
-
Immuneering reports 86% survival rate in pancreatic cancer trial
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) PT Raised to $3.50 at Jefferies
-
-
-
-
-
-
-
Immuneering Corporation (IMRX) Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX)
-
-
434,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

